FBXO10

Across TCGA pan-cancer cohorts, FBXO10 Mutation is linked to patient survival in 11 of 34 cancer types, making it a survival-associated FBXO10 data layer compared with 21 for mass-spec protein.

The strongest signal is observed in lung squamous cell carcinoma (LUSC), where higher FBXO10 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated FBXO10 expression acts as an unfavorable survival marker, although some lineages such as UCEC and COAD show a favorable association.

LUSC, UCEC, and KIRP are the cancer types where FBXO10 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUSC	DFS	Median	All	0.236	0.664	<.001	48	view →
UCEC	DFS	Median	All	0.941	0.625	.025	14	view →
KIRP	OS	Median	All	0.111	0.702	.001	12	view →
SCLC	OS	Median	All	0.082	0.822	<.001	12	view →
LIHC	OS	Median	All	0.144	0.704	.016	9	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
ESCA	DFS	Median	III,IV	0.103	0.442	.021	6	view →
SKCM	OS	Median	All	0.404	0.786	.017	6	view →
LUAD	DFS	Median	All	0.213	0.676	.030	3	view →
BRCA	OS	Median	All	0.769	0.963	.038	2	view →
COAD	DFS	Median	All	1.000	0.768	.045	2	view →

Pink = unfavorable, green = favorable. Showing the 11 strongest of 11 lineages.

FBXO10–LUSC (DFS)

Open the LUSC breakdown →